Receiving immune checkpoint inhibitors (ICIs) at any stage of treatment prolongs overall survival in patients with metastatic renal cell carcinoma (mRCC), investigators reported at IKCS Europe 2022.
Will Ince, MBBS, of Addenbooke’s Hospital in Cambridge, UK, and colleagues studied 423 “real-world” patients treated at their institution from January 2012 to July 2020. Of these, 285 patients (67%) received tyrosine kinase inhibitors (TKIs) and/or mammalian target of rapamycin (mTOR) kinase inhibitors only and 138 (33%) received ICIs at some stage of their treatment.
On multivariate analysis, ICI use for any line of treatment significantly prolonged overall survival (OS) compared with nonuse: median 34.2 months vs 11.3 months, Dr Ince reported. The OS advantage was 55% overall, and 45%, 49%, and 63% for the International Metastatic Renal Cell Carcinoma Database Consortium’s (IMDC) favorable, intermediate-, and poor-risk subgroups, respectively.
ICI users vs nonusers were significantly more likely have Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (91% vs 72%), IMDC favorable-risk disease (23% vs 11%), and younger age (63.9 vs 66.7 years), he reported.
“Treatment options for mRCC are manifold,” Dr Ince concluded in a study abstract. “Our data suggest that the use of ICI at any line of treatment provides a significant overall survival advantage, controlling for common clinical confounding variables.”
Ince W, et al. ‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC). Presented at IKCS 2022, April 22-24, 2022, Antwerp, Belgium. Poster 4.